Lixisenatide

Description

Lixisenatide · CAS 320367-13-3 · C215H347N61O65S. UNII 74O62BB01U.

Identification

Computed Descriptors

GHS Hazard Classification

Documented Uses

• Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus. It is also available in combination with [insulin glargine] for the same indication.
• Lixisenatide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents. Therapy with lixisenatide has not been associated with serum enzyme elevations or with episodes of clinically apparent liver injury.
• Breast Feeding; Lactation; Milk, Human; Hypoglycemic Agents; Incretins; Glucagon-Like Peptide-1 Agonists; GLP-1 Agonists
• Take at the same time every day.
• Take before a meal. Take lixisenatide within one hour before the first meal of the day.
• Established Pharmacologic Class [EPC] - GLP-1 Receptor Agonist

Synonyms

Lixisenatide; Adlyxin; Lyxumia; ZP10A peptide; 320367-13-3; ZP 10; AVE0010; AQVE-10010; AVE 0010; lixisenatida; lixisenatidum; AVE 010; AVE-010; ZP-10; AVE-0010; Des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide

Frequently Asked Questions

What are the CAS number and molecular formula of Lixisenatide?

CAS 320367-13-3; molecular formula C215H347N61O65S; molecular weight — g/mol.

What other names is Lixisenatide known by?

Lixisenatide, Adlyxin, Lyxumia, ZP10A peptide, 320367-13-3, ZP 10.

Is Lixisenatide classified as hazardous?

Hazard statements reported: H318, H361.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.